%A Modi,Natansh D. %A Tan,Jin Quan Eugene %A Rowland,Andrew %A Koczwara,Bogda %A Kichenadasse,Ganessan %A McKinnon,Ross A. %A Wiese,Michael D. %A Sorich,Michael J. %A Hopkins,Ashley M. %D 2020 %J Frontiers in Oncology %C %F %G English %K beta-blockers,Survival,breast cancer,HER2 positive,targeted therapy %Q %R 10.3389/fonc.2020.01130 %W %L %M %P %7 %8 2020-July-14 %9 Original Research %# %! Beta-blockers in HER2+ advanced cancer %* %< %T The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data %U https://www.frontiersin.org/articles/10.3389/fonc.2020.01130 %V 10 %0 JOURNAL ARTICLE %@ 2234-943X %X Introduction: Beta-blockers (BB) are commonly used to manage cardiovascular disease and may have benefits in controlling complications of anti-HER2 therapies. This study aimed to evaluate the association of pre-existing BB use with survival outcomes in patients initiating anti-HER2 therapy for advanced breast cancer (ABC).Materials and Methods: Data from clinical trials EMILIA, TH3RESA, MARIANNE, and CLEOPATRA was pooled. Cox proportional analysis was used to assess the association between pre-existing BB use with survival outcomes in patients initiating anti-HER2 therapies.Results: Of the 2,777 patients with HER2 positive ABC, 266 were using a BB at the time of anti-HER2 therapy initiation. BB use was associated with worse overall survival (OS) (adjusted HR = 1.27, 95% CI: 1.04–1.55). Sensitivity analysis in patients with pre-existing cardiovascular disease (CVD) also indicated that BB use was associated with worse OS (1.29, 1.02–1.63).Conclusion: In large high-quality data, BB use at the time of anti-HER2 therapy initiation for ABC was independently associated with worse OS, regardless of CVD status. The finding is contrary to pre-study hypotheses and findings in other BC subtypes. Future research should aim to gain a deeper understanding of the effects of BBs on specific BC subtypes, cancer types, and cancer treatments.